FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/23/2024
Back to search
Official data from USPTO
MYRIAMED
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MYRIAMED
ST13
US500000079350987Class
1, 5, 9, 42
Filing
79350987
Registration
7376414
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
11/23/2024
Trademark type
Word
Nice classes
1, 5, 9, 42
Filing date
04/07/2022
Registration date
05/07/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/07/2024
Last transaction
05/07/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
28
Owner location
DE
Examiner
ELLINGER FATHY, JESSICA
Law office
M10
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
myriamed GmbH
Representatives
Michael A. Whittaker Acuity Law Group
Technical classification
Nice Classes
Class 1Class 5Class 9Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemicals for use in industry and sciencein particular reagents for cultivation of cells and tissue; cells for research or for scientific purposescellsin particular genetically modified cellshuman cells and cells derived from induced pluripotent stem cellsin particular cardiomyocytes derived from human induced pluripotent stem cellsskeletal cells derived from human induced pluripotent stem cellsstroma cells derived from human induced pluripotent stem cellsneuronal cells derived from human induced pluripotent stem cells; biological tissuesother than for medical or veterinary purposestissues in particular engineered tissuesin particular tissue comprising cells derived from induced pluripotent stem cells and macroscale muscle tissuein particular human heart muscle constructed from cardiomyocytes derived from human induced pluripotent stem cellshuman skeletal muscle constructed from skeletal cells derived from human induced pluripotent stem cellshuman fibrotic tissue constructed from stroma cells derived from human induced pluripotent stem cellsconnective tissue constructed from connective tissue cells derived from human induced pluripotent stem cellsbrain tissue derived from human induced pluripotent stem cellsneuronal organoids; biological preparation for use in cell cultures other than for medical or veterinary use; biological tissue culturesother than for medical or veterinary purposes; biological tissue culturesother than for medical or veterinary purposesdisease models based on engineered tissue or engineered cells
Class 5
Pharmaceutical and veterinary preparationsin particular cells and tissues for treatment of cardiac diseasesdegenerative muscular diseasesfibrotic diseasesneurodegenerative diseasesconnective tissue diseases or disorders with impaired scaring and wound healing; pharmaceutical preparations for the renewal and regeneration of organs; pharmaceutical preparations for use in cellular therapy; biological tissue derived from stem cells for medical purposes; tissue-regenerative pharmaceutical preparations
Class 9
Scientific research and laboratory apparatus for drug screening or potency assays; cell culture apparatus for laboratory usein particular cell culture plates and tissue culture plates for the generation and/or cultivation of engineered tissue
Class 42
Scientific and industrial research in particular in the biochemicaldiagnostic or pharmaceutical fields; biochemical or pharmaceutical laboratory servicesin particular in the field of cultivation of cells and tissues; drug discovery servicesin particular drug discovery services based on tissue engineered organ platforms; scientific and technological services and research in the field of regenerative medicine; cell culture services for scientific and research purposesfor others
Publications
History of USPTO decisions and trademark events.
29 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/31/2024
FIMP
FINAL DISPOSITION PROCESSED
10/30/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/07/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/07/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/07/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
03/25/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/06/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
03/06/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/04/2024
GPNX
NOTIFICATION PROCESSED BY IB
02/26/2024
PUBO
PUBLISHED FOR OPPOSITION
02/20/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/07/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
02/07/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
02/01/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/31/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/18/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/11/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/11/2023
RFNT
REFUSAL PROCESSED BY IB
04/25/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/31/2023
RFRR
REFUSAL PROCESSED BY MPU
03/31/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/12/2023
CNRT
NON-FINAL ACTION WRITTEN
02/11/2023
DOCK
ASSIGNED TO EXAMINER
01/25/2023
MAFR
APPLICATION FILING RECEIPT MAILED
10/04/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/30/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
09/29/2022
Continuous trademark protection
Get notified about every new filing that threatens MYRIAMED or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.